Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Viktor Levitski

Christian Klein

Pablo Umana

Claudia Ferrara Koller

Maria Amann

Ekkehard Moessner

Guy Georges

Peter Bruenker

Sandra Grau-Richards

Christina Claus

Joerg Thomas Regula

Stefan Seeber

Georg Fertig

Laura Codarri-Deak

Ralf Hosse

Pablo Umaña

Tilman Schlothauer

Stefan Dengl

Jens Fischer

Joerg Benz

Valeria Lifke

Samuel Moser

Barbara Weiser

Laura Codarri Deak

Mario Perro

Adrian Zwick

Oliver Ploettner

Ildiko Wuensche

Sebastian Fenn

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety

The invention relates to antibody or antibody fragments thereof that bind to OX40, methods of producing these antibodies and fragments, and to methods of using the same.

Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Growing community of inventors

Schlieren, Switzerland

Viktor Levitski